GUANGZHOU, China, May 28, 2022 /PRNewswire/ — The morning of May 27, 2022Mr. Loh Tuck KeatConsul General of Singapore in Cantonand representatives of consulates general and chambers of commerce of eight countries, namely Malaysia, Philippines, Laos, Vietnam, Indonesia, Thailand and Cambodia, visited Guangzhou China-Singapore Knowledge City (CSGKC) and inspected Singapore Biosyngen Pte. ltd. (hereinafter referred to as Biosyngen). Officials from Guangzhou Foreign Affairs Bureau, Huangpu District, Guangzhou Development District Government, Guangzhou China-Singapore Knowledge City Construction Bureau and representatives of state-owned enterprises accompanied the visit.
The event was initiated by Mr. Loh Tuck KeatConsul General of Singapore in Cantonto further promote the construction of East Asia within the framework of the RCEP by virtue of the strengths and advantages of the CSGKC in terms of industrial establishment, technological innovation and international cooperation. With the construction of a main platform for economic and trade cooperation, comprehensive and high-quality cooperation between ASEAN countries and China is to be strengthened.
During their visit, the consuls and officials of ASEAN countries in Canton and chamber of commerce representatives inspected the largest commercial production base of immune cell drugs in south china of Biosyngen, which is designed, built and managed according to GMP standards. The production base is equipped with the most advanced production quality control facilities in the industry, realizing automated, fully enclosed and customized manufacturing, enabling rapid industrialization of cutting-edge technologies and achievements in biological research and providing patients with safe, high quality, affordable and premium immune cell therapy products.
Dr. Han Deping, CEO of Biosyngen, introduced the company’s pipeline products, scientific and technological achievements, scientific team and cooperative institutions as well as the industrial chain layout to the representatives of consulates and chambers of commerce. trade.
He said, as a model company of China–Singapore cooperation, the company will use national strategy and international opportunities, rely on its own advanced technology, take advantage of international cooperation, encourage RCEP member countries to build closer ties in biomedical technology cooperation and the exchange of talents. Biosyngen aims to rapidly translate rich clinical practice into China to provide patients around the world with quality and affordable products to improve the accessibility of disease treatment and benefit the majority of patients.
Teacher Jean-Paul ThieryChief Scientific Advisor and Chairman of Biosyngen’s Scientific Committee, presented the company’s products and technological advances to the consuls.
Teacher Jean-Paul Thiery said, EBV infection is closely linked to the development of many types of tumors, and Biosyngen insists on the combination of independent R&D and exclusive licensing. It has obtained the exclusive worldwide license of CAR-T and TCR-T products from the world’s leading research institutes for the treatment of EBV-related tumors. The company’s R&D team has established a multi-pipeline of products for unmet medical needs.
After the visit, representatives of consulates and chambers of commerce exchanged with the Biosyngen management team on the characteristics of the products, the advanced and differentiated technologies, the international environment of the biopharmaceutical industry, as well as the strategies for support, intellectual property protection, international talent exchange and business cooperation in the CSGKC.
Mr. Loh Tuck KeatConsul General of Singapore in Canton said, it is very gratifying to see that Biosyngen has gained such rapid development in CSGKC. Singaporeas the first ASEAN member country to complete the official RCEP approval process, will focus on promoting comprehensive and in-depth cooperation between China and ASEAN.
In biomedicine, he mentioned that RCEP reduced tariffs on products related to the biomedical industry, as well as the cost of exporting certain China advantageous products in the markets of the parties to the agreement, which ultimately benefits the populations of the member countries. It has also contributed to strengthening links with global supply chains, building the resilience of industrial chains and supply chains, highlighting the benefits of financing, reducing uncertainties regarding foreign investment and cooperation. between Chinese companies. Biosyngen is the link of China–Singapore Cooperation. The more open, diverse, friendly and convenient environment created by RCEP is conducive for Biosyngen to promote intra-regional cooperation in pharmaceutical R&D, in order to integrate deeply into the global industry.
The consuls and representatives also visited Biosyngen’s R&D facilities, laboratory and offices. Representatives had a wonderful and profound impression of Biosyngen’s production and R&D environment. The consuls said international exchanges and cooperation will promote closer contact and understanding between countries. Build a East Asia platform for economic and trade cooperation with China under RCEP will give ASEAN countries a head start. The CSGKC is attractive because of its continuous development dynamic. At present, China-ASEAN relations have become a successful model of regional cooperation in the Asia Pacific region and a striking example of promoting the construction of a community of human destiny.
At present, CSGKC has gradually formed an industrial structure led by six major industries such as biomedicine, smart manufacturing, new materials and new energy, and the industrial gathering effect is obvious. As a company anchored in the CSGKC, Biosyngen will fully play its particular role of “pioneer, leader and demonstrator” in the strategy of development through innovation and will become a new model of China–Singapore quality cooperation and development.